OncoMatch/Clinical Trials/NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Is NCT05652335 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies JNJ-79635322 for relapsed or refractory multiple myeloma.
Treatment: JNJ-79635322 — The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
have been treated with a proteasome inhibitor
Must have received: immunomodulatory drug
have been treated with an immunomodulatory drug (IMiD) agent
Must have received: anti-CD38-based therapy
have been treated with an anti-CD38-based therapy
Cannot have received: proteasome inhibitor
PI therapy within 14 days prior to the first dose of study treatment
Cannot have received: immunomodulatory drug
IMiD agent therapy within 7 days prior to the first dose of study treatment
Cannot have received: gene-modified adoptive cell therapy
Exception: not applicable for Part 2C participants
gene-modified adoptive cell therapy within 90 days
Cannot have received: CD3-redirecting therapy
Exception: not applicable for Part 2B or 2C participants
CD3-redirecting therapy within 21 days
Cannot have received: radiation therapy
radiotherapy within 14 days
Cannot have received: allogeneic transplant
Prior allogeneic transplant within 6 months before the start of study treatment administration
Cannot have received: autologous transplant
autologous transplant within 12 weeks before the start of study treatment administration
Lab requirements
Cardiac function
left ventricular ejection fraction (lvef) >=45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine, California
- University of California San Francisco · San Francisco, California
- Colorado Blood Cancer Institute · Denver, Colorado
- Icahn School of Medicine at Mt. Sinai · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05652335 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior proteasome inhibitor, immunomodulatory drug, gene-modified adoptive cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages